Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001068510 | SCV001233626 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-05-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 861895). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is present in population databases (rs754517317, gnomAD 0.0009%). This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2502 of the ATM protein (p.Gly2502Val). |
Ambry Genetics | RCV004030680 | SCV004911145 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-11-26 | criteria provided, single submitter | clinical testing | The c.7505G>T (p.G2502V) alteration is located in exon 50 (coding exon 49) of the ATM gene. This alteration results from a G to T substitution at nucleotide position 7505, causing the glycine (G) at amino acid position 2502 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |